+ Site Statistics
+ Search Articles
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ PDF Full Text
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Translate
+ Recently Requested

Endoscopic evidence of mucosal injury in patients taking ticlopidine compared with patients taking aspirin/nonsteroidal antiinflammatory drugs and controls

Endoscopic evidence of mucosal injury in patients taking ticlopidine compared with patients taking aspirin/nonsteroidal antiinflammatory drugs and controls

Journal of Clinical Gastroenterology 34(5): 529-532

Ticlopidine is a novel antiplatelet agent used alone or in combination with aspirin and anticoagulants in the treatment and prevention of various vascular diseases. Gastrointestinal side effects, including bleeding, have been reported with use of ticlopidine in most of the vascular prevention trials. We studied the endoscopic evidence of mucosal damage in patients taking ticlopidine compared with patients taking aspirin/nonsteroidal antiinflammatory drugs (NSAIDs) and matched controls. We performed a longitudinal review of gastrointestinal endoscopy, pharmacy databases, and medical records of patients referred to our service over a period of 6 months for endoscopic evaluation of upper gastrointestinal bleeding, unexplained anemia, or abdominal pain. Data were collected and analyzed for 55 patients taking ticlopidine, 77 age- and gender-matched patients taking aspirin or NSAIDs, and 560 age- and gender-matched control patients not taking any of these medications. The overall prevalence of ulcers was marginally higher in the aspirin/NSAID group than in the ticlopidine group (35% vs. 29%) and was significantly higher among patients taking aspirin, NSAIDs, or ticlopidine than among controls (15%). Gastritis was also noted more frequently in the aspirin/NSAID and ticlopidine groups than in the control group. Endoscopic evidence of esophagitis was significantly more frequent in the control group than in the aspirin/NSAID and ticlopidine groups. There was no significant difference across groups in the prevalence of ulcers, gastritis, or esophagitis. Patients taking ticlopidine are more likely to have endoscopic evidence of mucosal damage than matched control patients and are nearly as likely to have such damage as endoscopically evaluated patients taking aspirin or NSAIDs. However, these findings must be confirmed using prospective cohort data for patients in primary care settings, to avoid referral bias.

(PDF emailed within 0-6 h: $19.90)

Accession: 045958215

Download citation: RISBibTeXText

PMID: 11960063

DOI: 10.1097/00004836-200205000-00009

Related references

Intraoperative and Postoperative Bleeding Problems in Patients Taking Warfarin, Aspirin, and Nonsteroidal Antiinflammatory Agents. Dermatologic Surgery 23(5): 381-383, 1997

Gastroduodenal mucosal injury in patients taking low-dose aspirin and the role of gastric mucoprotective drugs: possible effect of rebamipide. Journal of Clinical Biochemistry and Nutrition 47(1): 27-31, 2010

Intraoperative and postoperative bleeding problems in patients taking warfarin, aspirin, and nonsteroidal antiinflammatory agents. A prospective study. Dermatologic Surgery 23(5): 381-3; Discussion 384-5, 1997

Blood pressure and cardiovascular outcomes in patients taking nonsteroidal antiinflammatory drugs. Cardiovascular Therapeutics 30(6): 342-350, 2013

Lack of Complications in Skin Surgery of Patients Receiving Clopidogrel as Compared with Patients Taking Aspirin, Warfarin, and Controls. Yearbook of Dermatology and Dermatologic Surgery 2011: 465-466, 2011

Lack of complications in skin surgery of patients receiving clopidogrel as compared with patients taking aspirin, warfarin, and controls. American Surgeon 76(1): 11-14, 2010

Upper gastrointestinal findings and fecal occult blood in patients with rheumatic diseases taking nonsteroidal antiinflammatory drugs. British Journal of Rheumatology 26(4): 295-298, 1987

Complications of cutaneous surgery in patients who are taking warfarin, aspirin, or nonsteroidal anti-inflammatory drugs. Archives of Dermatology 132(2): 161-166, 1996

Gastrointestinal complications in high-risk patients taking aspirin or nonsteroidal anti-inflammatory drugs and omeprazole. Current Gastroenterology Reports 5(6): 450-451, 2003

Bleeding Risk of Patients With Acute Venous Thromboembolism Taking Nonsteroidal Anti-Inflammatory Drugs or Aspirin. The Journal of Emergency Medicine 47(6): 755-756, 2014

Bleeding risk of patients with acute venous thromboembolism taking nonsteroidal anti-inflammatory drugs or aspirin. JAMA Internal Medicine 174(6): 947-953, 2014

Cost Effectiveness Associated with Helicobacter pylori Screening and Eradication in Patients Taking Nonsteroidal Anti-Inflammatory Drugs and/or Aspirin. Gut and Liver 7(2): 182-189, 2013

Evaluation of NT-proBNP and high sensitivity C-reactive protein for predicting cardiovascular risk in patients with arthritis taking longterm nonsteroidal antiinflammatory drugs. Journal of Rheumatology 38(6): 1071-1078, 2011

Bleeding after tooth extraction in patients taking aspirin and clopidogrel (Plavix®) compared with healthy controls. British Journal of Oral and Maxillofacial Surgery 54(5): 568-572, 2018

Does rebamipide prevent gastric mucosal injury in patients taking aspirin and clopidogrel?. Digestive Diseases and Sciences 59(8): 1671-1673, 2014